(Q54566447)

1 June 2018

title

Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. (English)

1 reference

1 June 2018

1 reference

Eleni-Kyriaki Vetsika

1

1 reference

1 June 2018

Georgios Konsolakis

2

1 reference

1 June 2018

Despoina Aggouraki

3

1 reference

1 June 2018

Athanasios Kotsakis

4

1 reference

1 June 2018

Elisavet Papadimitraki

5

1 reference

1 June 2018

Soultana Christou

6

1 reference

1 June 2018

Jeanne Menez-Jamet

7

1 reference

1 June 2018

Kostas Kosmatopoulos

8

1 reference

1 June 2018

Vassilis Georgoulias

9

1 reference

1 June 2018

Dimitris Mavroudis

10

1 reference

1 June 2018

publication date

20 August 2011

1 reference

1 June 2018

Cancer Immunology, Immunotherapy

published in

1 reference

1 June 2018

volume

61

1 reference

1 June 2018

issue

2

1 reference

1 June 2018

page(s)

157-168

1 reference

1 June 2018

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Tumor-specific shared antigenic peptides recognized by human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Telomeres and human disease: ageing, cancer and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Creation of human tumour cells with defined genetic elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Inhibition of telomerase limits the growth of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Regulatory T cells: key controllers of immunologic self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Regulatory T cells in immune surveillance and treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

Anti-CTL-associated antigen 4: are regulatory T cells a target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1093-4

10.1007/S00262-011-1093-4

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018